0000950170-24-073912.txt : 20240614
0000950170-24-073912.hdr.sgml : 20240614
20240614190008
ACCESSION NUMBER: 0000950170-24-073912
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240612
FILED AS OF DATE: 20240614
DATE AS OF CHANGE: 20240614
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: AFEYAN NOUBAR
CENTRAL INDEX KEY: 0001222012
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38753
FILM NUMBER: 241046533
MAIL ADDRESS:
STREET 1: C/O FLAGSHIP PIONEERING, INC.
STREET 2: 55 CAMBRIDGE PARKWAY, SUITE 800E
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Moderna, Inc.
CENTRAL INDEX KEY: 0001682852
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 813467528
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 325 BINNEY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: 6177146500
MAIL ADDRESS:
STREET 1: 325 BINNEY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
FORMER COMPANY:
FORMER CONFORMED NAME: Moderna Therapeutics, Inc.
DATE OF NAME CHANGE: 20160822
4
1
ownership.xml
4
X0508
4
2024-06-12
0001682852
Moderna, Inc.
MRNA
0001222012
AFEYAN NOUBAR
C/O FLAGSHIP PIONEERING, INC.
55 CAMBRIDGE PARKWAY, SUITE 800E
CAMBRIDGE
MA
02142
true
false
false
false
true
Common Stock
2024-06-12
4
S
false
700
142.9696
D
2328315
D
Common Stock
2024-06-12
4
S
false
408
144.4619
D
2327907
D
Common Stock
2024-06-12
4
S
false
1263
145.5748
D
2326644
D
Common Stock
2024-06-12
4
S
false
3031
146.5483
D
2323613
D
Common Stock
2024-06-12
4
S
false
6397
147.5498
D
2317216
D
Common Stock
2024-06-12
4
S
false
1601
148.613
D
2315615
D
Common Stock
2024-06-12
4
S
false
1400
149.3927
D
2314215
D
Common Stock
2024-06-12
4
S
false
200
150.24
D
2314015
D
Common Stock
3880328
I
By Flagship Ventures Fund IV, L.P.
Common Stock
747897
I
By Flagship Ventures Fund IV-Rx, L.P.
Common Stock
3924
I
By Flagship Pioneering, Inc.
These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on February 27, 2023, as amended on November 7, 2023.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $142.49 to $143.43, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
Includes shares received in distributions-in-kind from Flagship Ventures Fund IV, L.P. ("Flagship Fund IV") and Flagship Ventures Fund IV-Rx, L.P. ("Flagship Fund IV-Rx") made prior to the filing of this report in accordance with the exemptions afforded by Rule 16a-13 and Rule 16a-9 of the Securities Exchange Act of 1934, as amended.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $144.04 to $145.02, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $145.04 to $146.03, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $146.04 to $147.03, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $147.05 to $148.02, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $148.08 to $149.05, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $149.15 to $149.98, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $150.21 to $150.27, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
The shares are held directly by Flagship Fund IV. Flagship Ventures Fund IV General Partner LLC ("Flagship Fund IV GP") is the general partner of Flagship Fund IV. The reporting person is the sole manager of Flagship Fund IV GP and disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.
The shares are held directly by Flagship Fund IV-Rx. Flagship Fund IV GP is the general partner of Flagship Fund IV-Rx. The reporting person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.
The shares are held directly by Flagship Pioneering, Inc. ("Flagship Pioneering"). The reporting person is the CEO and sole stockholder of Flagship Pioneering and disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.
Noubar B. Afeyan, Ph.D. By: /s/ Noubar B. Afeyan, Ph.D.
2024-06-14